Literature DB >> 3382761

Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer.

A Paradiso1, V Lorusso, S Tommasi, F Schittulli, E Maiello, M De Lena.   

Abstract

The relationship between cell kinetics and hormonal status and the relevance of the cell kinetic variable on success of hormone-therapy in estrogen receptor positive (ER+) breast tumors were analyzed in patients with advanced disease. Cell kinetics were evaluated as in vitro 3H-thymidine labeling index (LI), and estrogen receptor (ER) and progesterone receptor (PgR) with the dextran-coated charcoal technique. The analyses performed on primary tumor or soft tissue metastases from 52 patients showed a general association between the presence of hormone receptors and low proliferative activity, or the absence of receptors and high proliferative activity (ER and L.I.: p greater than 0.05; PgR and L.I.: p = 0.05). However, hormonal status and cell kinetic status were unrelated in about 40% of the cases. Clinical response to additive hormonotherapy was analyzed in relation to pretreatment LI in 29 patients with ER+ tumors. Time to reach maximum response was significantly longer in slow than in fast proliferating tumors, but complete remission was reached in 88% of slow proliferating tumors compared to only 46% of fast proliferating tumors. These preliminary results show that ER+ fast proliferating tumors largely escape hormonal control, and if confirmed on larger series, could identify cell kinetics as an important tool to select patients who will benefit from hormonal treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3382761     DOI: 10.1007/bf01807555

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  15 in total

1.  Standards for the assessment of estrogen receptors in human breast cancer. Report of a workshop on September 29, 1972, at the Antoni van Leeuwenhoek-Huis, Amsterdam.

Authors: 
Journal:  Eur J Cancer       Date:  1973-05       Impact factor: 9.162

2.  Tritiated thymidine labeling index and response in human breast cancer.

Authors:  A Sulkes; R B Livingston; W K Murphy
Journal:  J Natl Cancer Inst       Date:  1979-03       Impact factor: 13.506

3.  Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response.

Authors:  L P Pertschuk; K B Eisenberg; A C Carter; J G Feldman
Journal:  Cancer       Date:  1985-04-01       Impact factor: 6.860

4.  The problem of nonresponding estrogen receptor-positive patients with advanced breast cancer.

Authors:  H Maass; W Jonat; G Stolzenbach; G Trams
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

5.  Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival.

Authors:  J S Meyer; J Y Lee
Journal:  Cancer Res       Date:  1980-06       Impact factor: 12.701

6.  Cell proliferation and its relationship to clinical features and relapse in breast cancers.

Authors:  C Gentili; O Sanfilippo; R Silvestrini
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

7.  Quantitative estrogen receptor values and growth of carcinoma of the breast before surgical intervention.

Authors:  K Antoniades; H Spector
Journal:  Cancer       Date:  1982-08-15       Impact factor: 6.860

8.  Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer.

Authors:  A Bertuzzi; M G Daidone; G Di Fronzo; R Silvestrini
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

9.  Correlation of cell-cycle kinetics, hormone receptors, histopathology, and nodal status in human breast cancer.

Authors:  R E Moran; M M Black; L Alpert; M J Straus
Journal:  Cancer       Date:  1984-10-15       Impact factor: 6.860

10.  Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer.

Authors:  T E Kute; H B Muss; D Anderson; K Crumb; B Miller; D Burns; L A Dube
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.